Carregant...
The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non‐small‐cell lung cancer: A systematic review and meta‐analysis
BACKGROUND: Lung cancer is the leading cause of cancer‐related deaths worldwide and the prognosis remains poor. The recent introduction of the immune checkpoint inhibitor (ICI), or plus chemotherapy, both resulted in the survival benefit for patients with advanced non‐small‐cell lung cancer (NSCLC),...
Guardat en:
| Publicat a: | J Cell Physiol |
|---|---|
| Autors principals: | , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley and Sons Inc.
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7028135/ https://ncbi.nlm.nih.gov/pubmed/31693178 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcp.29371 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|